615 results on '"Sudo, Kazuki"'
Search Results
2. Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
3. Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine
4. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
5. Case study observational research: inflammatory cytokines in the bronchial epithelial lining fluid of COVID-19 patients with acute hypoxemic respiratory failure
6. Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
7. Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
8. Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
9. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer
10. Trop-2 expression and the tumor immune microenvironment in cervical cancer
11. Changes in EEG frequency characteristics during sevoflurane general anesthesia: feature extraction by variational mode decomposition
12. Prediction of acute lung injury assessed by chest computed tomography, oxygen saturation/fraction of inspired oxygen ratio, and serum lactate dehydrogenase in patients with COVID-19
13. Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy
14. Changes in HER3 expression profiles between primary and recurrent gynecological cancers
15. Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma
16. Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
17. Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials
18. Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
19. Practical consideration for successful sequential tumor biopsies in first-in-human trials
20. Wavelet transform-based mode decomposition for EEG signals under general anesthesia.
21. Identification of novel SSX1 fusions in synovial sarcoma
22. Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant
23. Impact of untreated diabetes and COVID-19-related diabetes on severe COVID-19
24. Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study
25. Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
26. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
27. High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
28. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study
29. Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma
30. Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors.
31. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience
32. A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
33. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project
34. A novel combination of serum microRNAs for the detection of early gastric cancer
35. Multicenter Prospective Study in HER2-Positive Early Breast Cancer for Detecting Minimal Residual Disease by Circulating Tumor DNA Analysis With Neoadjuvant Chemotherapy: HARMONY Study.
36. Increased Insulin Requirements in Severe Cases of Covid-19 are Higher Than in Moderate Cases.
37. Identification of barriers to implementation of precision oncology in patients with rare cancers
38. Potential marker subset of blood-circulating cytokines on hematopoietic progenitor-to-Th1 pathway in COVID-19
39. Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
40. Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
41. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma
42. Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine
43. Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
44. EP155/#758 The efficacy and safety of lenvatinib plus pembrolizumab in patients with recurrent endometrial cancer; a Japanese single institutional experience
45. MO10-5 Germline and somatic whole exome sequencing identifies a novel candidate gene in double primary BCRA-associated cancers
46. MO42-6 Analysis of sperm preservation in patients with mediastinal germ cell tumor patients
47. MO41-6 Trastuzumab-deruxtecan and blood inflammatory markers in HER2-positive metastatic breast cancer
48. MO33-2 Retrospective analysis of urothelial carcinoma treated with enfortumab vedotin at our institution
49. MO9-1 Clinical characteristics of HER2-low stage I triple-negative breast cancer
50. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.